Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 4/20 | 0.59 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | CTSL | P07711 | 1/20 | 0.48 |
| ▸ | CTSB | P07858 | 1/20 | 0.48 |
| ▸ | GLA | P06280 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.46 |
| ▸ | RELA | Q04206 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13636416 | 1.00 | HPGD (0.59) | HPGDHSD11B1MEN1KMT2ACTSL | |
| SCHEMBL6392805 | 0.98 | HPGD (0.56) | HPGDHSD11B1MEN1KMT2ACTSL | |
| SCHEMBL17664591 | 0.87 | FAAH (0.50) | HPGDHSD11B1MEN1KMT2AGLA | |
| SCHEMBL8848118 | 0.85 | HPGD (0.56) | HPGDHSD11B1MEN1KMT2ACTSL | |
| SCHEMBL8847821 | 0.82 | ALDH1A1 (0.56) | HPGDALDH1A1EPHX1 | |
| SCHEMBL8847507 | 0.81 | CASP2 (0.56) | HPGDALDH1A1EPHX1 | |
| SCHEMBL6063246 | 0.80 | CTSL (0.66) | HPGDMEN1KMT2ACTSLCTSB | |
| SCHEMBL8847408 | 0.80 | HPGD (0.54) | HPGDMEN1KMT2ACTSLCTSB | |
| SCHEMBL5245833 | 0.80 | HPGD (0.63) | HPGDMEN1KMT2ACTSLCTSB | |
| SCHEMBL8393928 | 0.80 | HPGD (0.63) | HPGDMEN1KMT2ACTSLCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240116910-A1 | Heterocycles as WIP1 Inhibitors | PMV PHARMACEUTICALS, INC. | 2024-04-11 | — | — | US | disclosed |
| US-20160137639-A1 | TRIAZOLE-ISOXAZOLE COMPOUND AND MEDICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2016-05-19 | — | — | US | disclosed |
| US-20160137639-A1 | TRIAZOLE-ISOXAZOLE COMPOUND AND MEDICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2016-05-19 | — | — | US | disclosed |
| WO-2014065413-A1 | TRIAZOLE-ISOXAZOLE COMPOUND AND MEDICAL USE THEREOF | 日本たばこ産業株式会社 (JP) | 2014-05-01 | — | — | WO | disclosed |
| EP-1444201-A1 | 2-(3-SULFONYLAMINO-2-OXOPYRROLIDIN-1-YL)PROPANAMIDES AS FACTOR XA INHIBITORS | GLAXO GROUP LIMITED (GB) | 2004-08-11 | — | — | EP | disclosed |
| WO-2003043981-A1 | 2-(3-SULFONYLAMINO-2-OXOPYRROLIDIN-1-YL)PROPANAMIDES AS FACTOR XA INHIBITORS | GLAXO GROUP LIMITED (GB) | 2003-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240116910-A1 | Heterocycles as WIP1 Inhibitors | WAPL, WHR1, G3BP1 | HPGD 1279/4885HSD11B1 3313/4885MEN1 1607/4885 |
| US-20160137639-A1 | TRIAZOLE-ISOXAZOLE COMPOUND AND MEDICAL USE THEREOF | CYP3A7, CYP2C19, CYP3A5 | HPGD 841/4885HSD11B1 134/4885MEN1 1076/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.